TY - JOUR
T1 - Modifiable risk factors to reduce renal cell carcinoma incidence
T2 - Insight from the PLCO trial
AU - Gelfond, Jonathan
AU - Al-Bayati, Osamah
AU - Kabra, Aashish
AU - Iffrig, Kevan
AU - Kaushik, Dharam
AU - Liss, Michael A.
N1 - Publisher Copyright:
© 2018
PY - 2018/7
Y1 - 2018/7
N2 - Introduction: Identify modifiable factors contributing to renal cell carcinoma in the PCLO to target disease prevention and reduce health care costs. Methods: The prostate, lung, colorectal, and ovarian database were queried for the primary outcome of kidney cancer. Demographics were investigated, specifically focusing on modifiable risk factors. Statistical analysis includes the Student t-test for continuous variables, chi-squared or Fisher's exact tests for dichotomous and categorical variables for bivariate analysis. The Cox proportional hazards model was used in a multivariate time-to-event analysis. Results: We investigate existing data relating specifically to renal cancer. After missing data were excluded, we analyzed 149,683 subjects enrolled in the prostate, lung, colorectal, and ovarian trial and noted 0.5% (n = 748) subjects developed renal cancer. Age, male gender, body mass index, diabetes, and hypertension were all significant associated with renal cancer in bivariate analysis (P<0.05). Men have a significant increased risk of kidney cancer over women (hazard ratio [HR] = 1.85; 95% CI: 1.58–2.16; P<0.0001). Nonmodifiable risk factors that are associated with kidney cancer include age (HR = 1.05; 95% CI: 1.01; 1.05, P = 0.001). Modifiable risk factors include obesity measured by body mass index (HR = 1.05; 95% CI: 1.02–1.07; P<0.0001), hypertension (HR = 1.32; 95% CI: 1.13–1.54; P = 0.0004), and smoking in pack-years (HR = 1.04; 95% CI: 1.02–1.07; P = 0.0002). Conclusions: Obesity, hypertension, and smoking are the 3 modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma.
AB - Introduction: Identify modifiable factors contributing to renal cell carcinoma in the PCLO to target disease prevention and reduce health care costs. Methods: The prostate, lung, colorectal, and ovarian database were queried for the primary outcome of kidney cancer. Demographics were investigated, specifically focusing on modifiable risk factors. Statistical analysis includes the Student t-test for continuous variables, chi-squared or Fisher's exact tests for dichotomous and categorical variables for bivariate analysis. The Cox proportional hazards model was used in a multivariate time-to-event analysis. Results: We investigate existing data relating specifically to renal cancer. After missing data were excluded, we analyzed 149,683 subjects enrolled in the prostate, lung, colorectal, and ovarian trial and noted 0.5% (n = 748) subjects developed renal cancer. Age, male gender, body mass index, diabetes, and hypertension were all significant associated with renal cancer in bivariate analysis (P<0.05). Men have a significant increased risk of kidney cancer over women (hazard ratio [HR] = 1.85; 95% CI: 1.58–2.16; P<0.0001). Nonmodifiable risk factors that are associated with kidney cancer include age (HR = 1.05; 95% CI: 1.01; 1.05, P = 0.001). Modifiable risk factors include obesity measured by body mass index (HR = 1.05; 95% CI: 1.02–1.07; P<0.0001), hypertension (HR = 1.32; 95% CI: 1.13–1.54; P = 0.0004), and smoking in pack-years (HR = 1.04; 95% CI: 1.02–1.07; P = 0.0002). Conclusions: Obesity, hypertension, and smoking are the 3 modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma.
KW - Blood pressure
KW - Body mass index
KW - Hypertension
KW - Kidney cancer
KW - Lifestyle
KW - Modifiable risk factors
KW - Obesity
KW - Prevention
KW - Renal cancer
KW - Renal cell cancer
KW - Smoking
UR - http://www.scopus.com/inward/record.url?scp=85047203326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047203326&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2018.04.011
DO - 10.1016/j.urolonc.2018.04.011
M3 - Article
C2 - 29779672
AN - SCOPUS:85047203326
SN - 1078-1439
VL - 36
SP - 340.e1-340.e6
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 7
ER -